Lisata Therapeutics Announced The Treatment Of The First Patient In The Head And Neck Squamous Cell Carcinoma Cohort Of The BOLSTER Trial, Enrollment Of 120 Patients Is Expected To Be Completed In 2H Of 2024
Portfolio Pulse from Benzinga Newsdesk
Lisata Therapeutics has announced the treatment of the first patient in the Head and Neck Squamous Cell Carcinoma cohort of the BOLSTER trial. The company expects to complete the enrollment of 120 patients in the second half of 2024.
September 12, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lisata Therapeutics' announcement of the first patient treatment in the BOLSTER trial could potentially boost investor confidence in the company's clinical progress.
The initiation of patient treatment in a clinical trial is a significant milestone for any biotech company. This news indicates that Lisata Therapeutics is making progress in its clinical trials, which could potentially boost investor confidence and positively impact the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100